Analyst Predicts Black Box Warning For Byetta

Law360, New York (September 3, 2008, 12:00 AM EDT) -- Amid cases of severe pancreatitis in patients taking the diabetes drug Byetta — and two deaths linked to the injectable medication — a financial analyst said Tuesday that the U.S. Food and Drug Administration might soon require a top-level warning label.

"We think Byetta could get a black box pancreatitis warning," analyst Adam Cutler of Canaccord Adams Inc. said in a research note, which also stated that “the FDA suspects Byetta causes pancreatitis.”

Amylin Pharmaceuticals had no immediate comment on the matter Wednesday.

In a statement...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.